Combination therapy for diabetes
Results from a UF Health pilot study have led to a new national trial investigating a combination treatment for individuals newly diagnosed with Type 1 diabetes.
Results from a UF Health pilot study have led to a new national trial investigating a combination treatment for individuals newly diagnosed with Type 1 diabetes.
Several studies to date have found that people with type 1 diabetes (T1D) tend to have celiac disease more often than individuals in the general population. Michael Haller, MD, a pediatric endocrinologist at UF Health, told Medscape Medical News in a recent interview that screening every type 1 diabetes patient for the disease presents a unique clinical challenge.
UF and UF Health faculty, postdoctoral fellows, and graduate students submitted a record number of original research presentations for the American Diabetes Association’s 74th Scientific Sessions held June 13-17, 2014 at the Moscone Center in San Francisco, California. This year's submissions represent one of the largest showcases of research emanating from UF.
Combining two different medications could help patients with Type 1 diabetes at least partially regain the ability to produce their own insulin, according to UF Health pediatric endocrinologist Michael Haller, MD.
A new University of Florida pilot study is helping researchers better understand the trajectory of Type 1 diabetes and may one day help lead to interventions to prevent the disease.
In a new study co-authored by UF Diabetes Faculty, researchers noted markedly different diabetes self-management techniques between children with excellent glycemic control and their poor-glycemic counterparts. This knowledge, made possible by the T1D Exchange Network, may help improve glycemic control among current and future type 1 diabetes patients.
"UF works to unlock causes and cures so kids like Matt Danner won’t be sidelined by their disease." Florida Magazine recently featured an article highlighting the UF Diabetes Center researchers, physicians, and a special patient, Matt Danner.